(Albany, US) DelveInsight has launched a new report on Sarcopenia Pipeline
Sarcopenia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Sarcopenia market. A detailed picture of the Sarcopenia pipeline landscape is provided, which includes the disease overview and Sarcopenia treatment guidelines. The assessment part of the report embraces in-depth Sarcopenia commercial assessment and clinical assessment of the Sarcopenia pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Sarcopenia is a condition which is characterized by loss of muscle mass, muscle strength and functional muscle impairment with ageing. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases. The etiology of sarcopenia is a constellation of factors involving the aging neuromuscular machinery (motor unit number and efficiency, muscle architecture and orientation, fiber type distibution), reduced anabolic hormone levels, muscle disuse, and inflammation driven by environmental, genetic and behavioral factors
Request for free sample page:- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight
Sarcopenia Pipeline Development Activities
The report provides insights into:
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc
Sarcopenia Pipeline
Research is underway to identify therapeutic targets and develop a curative therapy for the treatment of sarcopenia. But, the current sarcopenia pipeline is poor with very few industry-funded trials. Some of the potential candidates are elaborated below.
Emerging drugs included in the report
Table of content
1. Report Introduction
2. Sarcopenia
3. Sarcopenia Current Treatment Patterns
4. Sarcopenia – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Sarcopenia Late Stage Products (Phase-III)
7. Sarcopenia Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Sarcopenia Discontinued Products
13. Sarcopenia Product Profiles
14. Sarcopenia Key Companies
15. Sarcopenia Key Products
16. Dormant and Discontinued Products
17. Sarcopenia Unmet Needs
18. Sarcopenia Future Perspectives
19. Sarcopenia Analyst Review
20. Appendix
21. Report Methodology
22. About DelveInsight
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/